Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Ordonez KathyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-37,106Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Ordonez KathyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-324,515Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Ordonez KathyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:37,106Price:$2.63
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Ordonez KathyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:324,515Price:$2.90
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Meline David WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:40,000Price:$4.40
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Farmer MicheleOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,968Price:$4.87
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Van Oene MarkOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,186Price:$4.87
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Kim Susan G.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,275Price:$4.87
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Henry Christian OOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,177Price:$4.87
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Mohr MarshallOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-25,000Price:--
Filings by filing date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Ordonez KathyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-37,106Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Ordonez KathyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-324,515Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Ordonez KathyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:37,106Price:$2.63
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Ordonez KathyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:324,515Price:$2.90
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Meline David WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:40,000Price:$4.40
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Farmer MicheleOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,968Price:$4.87
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Van Oene MarkOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,186Price:$4.87
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Kim Susan G.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,275Price:$4.87
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Henry Christian OOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,177Price:$4.87
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Mohr MarshallOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-25,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1305 O'brien Drive MENLO PARK CA 94025 |
Tel: | N/A |
Website: | https://www.pacb.com |
IR: | See website |
Key People | ||
Christian O. Henry President, Chief Executive Officer, Director | Susan G Kim Chief Financial Officer | Mark Van Oene Chief Operating Officer |
Michele Farmer Chief Accounting Officer, Vice President | Brett Atkins General Counsel, Corporate Secretary | Jeff Eidel Chief Commercial Officer |
Business Overview |
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time. |
Financial Overview |
For the fiscal year ended 31 December 2023, Pacific Biosciences of California Inc revenues increased 56% to $200.5M. Net loss decreased 2% to $306.7M. Revenues reflect Instrument revenue segment increase from $48.7M to $120.5M, Consumable revenue segment increase of 6% to $63.4M, North America segment increase of 52% to $105.4M, Asia Pacific segment increase of 51% to $54.5M. Lower net loss reflects Other income, net increase from $7.6M to $32.7M (income). |
Employees: | 796 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $721.58M as of Dec 31, 2023 |
Annual revenue (TTM): | $200.52M as of Dec 31, 2023 |
EBITDA (TTM): | -$302.27M as of Dec 31, 2023 |
Net annual income (TTM): | -$306.74M as of Dec 31, 2023 |
Free cash flow (TTM): | -$268.02M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $261.32M as of Dec 31, 2023 |
Shares outstanding: | 272,343,392 as of Apr 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |